Watson to establish global r&d centre in New Jersey

Published: 31-Jan-2012
Research & Development Finance

Will invest US$5.4m in outfitting the new facility


Global pharmaceutical firm Watson Pharmaceuticals is to establish a Global R&D Technology Center in North Brunswick, New Jersey.

The company has signed a lease for a 32,000ft2 of space and plans to retrofit approximately 19,000ft2 for product development and analytical laboratories. The remaining 13,000ft2 will accommodate future expansion.

Watson Pharmaceuticals intends to invest approximately US$4.5m in outfitting the new facility.

The facility, which should be completed in the spring, will employ approximately 50 scientists, chemists, engineers and support staff.

Watson’s president and ceo Paul Bisaro said the location of the new Global R&D Technology Center will enable Watson ‘to leverage our proximity to such educational centres of excellence as Rutgers University’.

The centre will become Watson’s state-of-the-art facility for developing generic pharmaceutical products, in particular for inhalation technology and respiratory products, with the ability to conduct formulation development and analytical testing.

In addition, it will focus on process analytical technology, packaging development, pharmaceutical technology, inhalation technology and new technology evaluation.

  • Companies:
  • Actavis
See more

You may also like

Regulatory

Pharma companies fined £45m for 'pay-for-delay'

Read more
GSK’s conduct, in making payments to induce companies to delay their efforts to enter the UK paroxetine market infringed the competition law prohibition on abuse of a dominant position

Trending Articles

  1. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  2. Ardena's nanomedicines facility marks expansion with first GMP approval The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
  3. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  4. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Pharma companies fined £45m for 'pay-for-delay'

GSK’s conduct, in making payments to induce companies to delay their efforts to enter the UK paroxetine market infringed the competition law prohibition on abuse of a dominant position
Regulatory

Schizophrenia – cariprazine

Drug treatment for schizophrenia has relied for many years on antipsychotics such as chlorpromazine and haloperidol, but side-effects limited their usefulness, particularly in terms of compliance
Finance

Amneal to purchase generics business of Actavis Australia

Financial terms are not disclosed by the companies
Regulatory

Actavis gets go-ahead from European Commission to purchase Allergan

Deal will create one of the top 10 global pharmaceutical companies by sales revenue
Finance

Actavis plans to change name to Allergan after acquisition closes

Will retain Actavis name for certain geographic regions and product portfolios
Research & Development

Actavis to divest Pharmatech to TPG

TPG to focus on growth and development of innovative products
Finance

Actavis to buy Auden Mckenzie for £306m

A move that will make Actavis the leading supplier of generics in the UK
Subscribe now